La catena delle opzioni mostra i dati chiave delle opzioni azionarie di RenovoRx a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per RenovoRx..

RenovoRx (NASDAQ:RNXT) Azioni, Catena delle Opzioni

RenovoRx

RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.

RenovoRx Inc

Upland Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPLD#NASDAQ">UPLD</a>) reported quarterly earnings of $0.42 per share which beat the analyst consensus estimate of $0.17 by 147.06 percent. This is a 27.27 percent increase over earnings of $0.33 per share from the same period last year. The company reported quarterly sales of $66.69 million which missed the analyst consensus estimate of $66.78 million by 0.13 percent. This is a 10.02 percent decrease over sales of $74.12 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

News

UPLD

Upland Software Q3 Adj $0.42 Beats $0.17 Estimate, Sales $66.69M Miss $66.78M Estimate

Guidance

REZI

Resideo Sees Q4 Adj. EPS $0.51-$0.61; Revenue $1.815B-$1.855B

TaskUs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TASK#NASDAQ">TASK</a>) reported quarterly earnings of $0.14 per share which met the analyst consensus estimate. The company reported quarterly sales of $255.300 million which beat the analyst consensus estimate of $245.492 million by 4.00 percent. This is a 13.15 percent increase over sales of $225.626 million the same period last year.

TASK

TaskUs Q3 2024 GAAP EPS $0.14, Inline, Sales $255.300M Beat $245.492M Estimate

LightPath Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPTH#NASDAQ">LPTH</a>) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.05) by 20 percent. The company reported quarterly sales of $8.400 million which beat the analyst consensus estimate of $8.334 million by 0.79 percent. This is a 4.00 percent increase over sales of $8.077 million the same period last year.

LPTH

LightPath Technologies Q1 2025 GAAP EPS $(0.04) Beats $(0.05) Estimate, Sales $8.400M Beat $8.334M Estimate

Financial Outlook
OneStream is providing the following guidance for the fourth quarter of 2024 and the full year 2024:
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Q4'24</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">FY24</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Total Revenue</td>
<td colspan="1" rowspan="1">$127M - $129M</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$484M - $486M</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Non-GAAP Operating Margin</td>
<td colspan="1" rowspan="1">0% - 2%</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">(2)% - (1)%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Non-GAAP Net Income per Share</td>
<td colspan="1" rowspan="1">$0.01 - $0.03</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$0.06 - $0.08</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Equity-Based Compensation</td>
<td colspan="1" rowspan="1">$50M - $55M</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$315M - $320M</td>
</tr>
</tbody>
</table>
</figure>
OneStream has not provided a reconciliation of its forward outlook for non-GAAP operating margin and non-GAAP net loss per share to their most directly comparable GAAP financial measures in reliance on the unreasonable efforts exception provided under Item 10(e)(1)(i)(B) of Regulation S-K. OneStream is unable to predict with reasonable certainty the amount and timing of adjustments that are used to calculate these non-GAAP financial measures, particularly related to equity-based compensation and its related tax effects.

OneStream Sees Q4 EPS $0.01-$0.03 Vs $0.01 Est.; Revenue $127M-$129M Vs $126.63M Est.; FY24 EPS $0.06-$0.08 Vs $(0.02) Est.; Revenue $484M-$486M Vs $478.55M Est.

FROG

JFrog Sees Q4 2024 Revenue $113.5M-$114.5M Vs $105.598M Est.; Adj EPS $0.13-$0.15 Vs $0.11 Est.

Leafly Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFLY#NASDAQ">LFLY</a>) reported quarterly losses of $(0.46) per share which beat the analyst consensus estimate of $(0.85) by 45.88 percent. This is a 58.18 percent increase over losses of $(1.10) per share from the same period last year. The company reported quarterly sales of $8.35 million which missed the analyst consensus estimate of $8.38 million by 0.32 percent. This is a 21.07 percent decrease over sales of $10.58 million the same period last year.

LFLY

Leafly Holdings Q3 EPS $(0.46) Beats $(0.85) Estimate, Sales $8.35M Miss $8.38M Estimate

Civitas Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CIVI#NYSE">CIVI</a>) reported quarterly earnings of $1.99 per share which met the analyst consensus estimate. The company reported quarterly sales of $1.27 billion which missed the analyst consensus estimate of $1.33 billion by 4.16 percent. This is a 22.78 percent increase over sales of $1.04 billion the same period last year.

CIVI

Civitas Resources Q3 2024 Adj EPS $1.99, Inline, Sales $1.27B Miss $1.33B Estimate

JAMF

Jamf Sees FY24 Revenue $626.3M-$627.3M Vs $624.072M Est; Sees Q4 Revenue $161.9M-$162.9M.

Open Lending (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPRO#NASDAQ">LPRO</a>) sees Q4 sales of $22.000 million-26.000 million vs $30.29 million estimate.

LPRO

Open Lending Sees Q4 Sales $22.000M-26.000M vs $30.29M Est

JFrog (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FROG#NASDAQ">FROG</a>) reported quarterly earnings of $0.15 per share which beat the analyst consensus estimate of $0.11 by 36.36 percent. The company reported quarterly sales of $109.06 million which beat the analyst consensus estimate of $105.60 million by 3.27 percent. This is a 23.04 percent increase over sales of $88.64 million the same period last year.

JFrog Q3 2024 Adj EPS $0.15 Beats $0.11 Estimate, Sales $109.06M Beat $105.60M Estimate

XPOF

Xponential Fitness Reiterates FY24 Revenue $310M-$320M Vs $314.401M Est.

Dynavax Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DVAX#NASDAQ">DVAX</a>) reported quarterly earnings of $0.12 per share which beat the analyst consensus estimate of $0.11 by 9.09 percent. The company reported quarterly sales of $80.630 million which missed the analyst consensus estimate of $84.166 million by 4.20 percent. This is a 15.99 percent increase over sales of $69.514 million the same period last year.

DVAX

Dynavax Technologies Q3 2024 GAAP EPS $0.12 Beats $0.11 Estimate, Sales $80.630M Miss $84.166M Estimate

QDEL

QuidelOrtho Sees FY24 Revenue $2.75B-$2.80B Vs $2.713B Est; Sees Adj EPS $1.69-$1.91 Vs $1.73 Est.

Hannon Armstrong Sustainable Infrastructure Capital

HASI

HA Sustainable Infrastructure Capital Confirms Guidance For Adjusted EPS And Dividend Payout Ratio; Continues To Expect Annual Adjusted EPS To Grow At A Compounded Annual Rate Of 8%-10% From 2024-2026, Relative To The 2023 Baseline Of $2.23 Per Share, Which Is Equivalent To A 2026 Midpoint Of $2.89 Per Share; Expects Distributions Of Annual Dividends Per Share From 2024-2026 At A Payout Ratio Of Between 60%-70% Of Annual Adjusted EPS

GoPro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GPRO#NASDAQ">GPRO</a>) reported quarterly sales of $258.90 million which beat the analyst consensus estimate of $255.00 million by 1.53 percent. This is a 12.03 percent decrease over sales of $294.30 million the same period last year.

GPRO

GoPro Q3 Sales $258.90M Beat $255.00M Estimate

Innodata (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INOD#NASDAQ">INOD</a>) sees FY2024 sales of $163.137 million-166.608 million vs $137.46 million estimate.

INOD

Innodata Sees FY2024 Sales to between 88% and 92% year-over-year.

Applied Optoelectronics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAOI#NASDAQ">AAOI</a>) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.17) by 23.53 percent. The company reported quarterly sales of $65.15 million which beat the analyst consensus estimate of $62.60 million by 4.08 percent. This is a 4.16 percent increase over sales of $62.55 million the same period last year.

AAOI

Applied Optoelectronics Q3 2024 Adj EPS $(0.21) Misses $(0.17) Estimate, Sales $65.15M Beat $62.60M Estimate

Jamf Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAMF#NASDAQ">JAMF</a>) reported quarterly earnings of $0.10 per share which missed the analyst consensus estimate of $0.16 by 37.5 percent. The company reported quarterly sales of $159.300 million which beat the analyst consensus estimate of $157.566 million by 1.10 percent. This is a 11.69 percent increase over sales of $142.625 million the same period last year.

Jamf Holding Q3 2024 Adj. EPS $0.10 Misses $0.16 Estimate, Sales $159.300M Beat $157.566M Estimate

Iovance Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOVA#NASDAQ">IOVA</a>) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.30) by 6.67 percent. The company reported quarterly sales of $58.555 million which beat the analyst consensus estimate of $53.808 million by 8.82 percent. This is a 12.39K percent increase over sales of $469.000 thousand the same period last year.

IOVA

Iovance Biotherapeutics Q3 2024 GAAP EPS $(0.28) Beats $(0.30) Estimate, Sales $58.555M Beat $53.808M Estimate

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pre-market stock movers are worth checking out as we get into all of the hottest news happening on Tuesday morning!



Moving stocks this morning are earnings reports, clinical trial data and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Biophytis (NASDAQ:<a href="https://investorplace.com/stock-quotes/bpts-stock-quote/">BPTS</a>) stock is rocketing close to 50% after <a href="https://www.nasdaq.com/press-release/biophytis-announces-its-2023-financial-results-and-provides-an-update-on-its-business">announcing its 2023 results</a>.</li>



<li>MyMD Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/mymd-stock-quote/">MYMD</a>) shares are rising over 26% after revealing a <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318224188&amp;type=PDF&amp;symbol=MYMD&amp;cdn=8720a94b32a7a67a8aeafa7ccea08ffe&amp;companyName=MyMD+Pharmaceuticals+Inc.&amp;formType=8-K&amp;formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2024-04-08">securities purchase agreement</a>.</li>



<li>Acorda Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/acor-stock-quote/">ACOR</a>) stock is soaring more than 26% <a href="https://www.nasdaq.com/press-release/acorda-therapeutics-announces-nasdaq-delisting-notification-2024-04-03">ahead of its delisting</a>.</li>



<li>Addex Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/adxn-stock-quote/">ADXN</a>) shares are surging over 26% without any clear news this morning.</li>



<li>TuanChe (NASDAQ:<a href="https://investorplace.com/stock-quotes/tc-stock-quote/">TC</a>) stock is gaining nearly 17% despite a lack of news today.</li>



<li>Anghami (NASDAQ:<a href="https://investorplace.com/stock-quotes/angh-stock-quote/">ANGH</a>) shares are increasing more than 16% <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318224555&amp;type=PDF&amp;symbol=ANGH&amp;cdn=55a7014ffb2fa2fae4e6fc7d8965ee6d&amp;companyName=Anghami+Inc.&amp;formType=SC+13D&amp;formDescription=General+statement+of+acquisition+of+beneficial+ownership&amp;dateFiled=2024-04-08">following an investor update</a>.</li>



<li>MediaCo (NASDAQ:<a href="https://investorplace.com/stock-quotes/mdia-stock-quote/">MDIA</a>) stock is climbing over 14% on Tuesday morning.</li>



<li>Brainstorm Cell (NASDAQ:<a href="https://investorplace.com/stock-quotes/bcli-stock-quote/">BCLI</a>) shares are getting a more than 13% boost with an update on its <a href="https://www.nasdaq.com/press-release/brainstorm-cell-therapeutics-announces-agreement-with-fda-on-a-special-protocol">Phase 3 clinical trial</a>.</li>



<li>Destiny Tech100 (NYSE:<a href="https://investorplace.com/stock-quotes/dxyz-stock-quote/">DXYZ</a>) stock is jumping over 13% as it <a href="https://seekingalpha.com/article/4682523-destiny-tech100-inc-dxyz-rose-800-percent-in-just-days-a-closer-look">continues a recent rally</a>.</li>



<li>RenovoRx (NASDAQ:<a href="https://investorplace.com/stock-quotes/rnxt-stock-quote/">RNXT</a>) shares are up more than 12% on <a href="https://www.nasdaq.com/press-release/renovorx-announces-%2411.1-million-at-market-private-placement-2024-04-08">an offer to take it private</a>.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Vincerx Pharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/vinc-stock-quote/">VINC</a>) stock is crashing over 53% on <a href="https://www.nasdaq.com/press-release/vincerx-pharma-presents-positive-preliminary-phase-1-data-for-vip236-and-updates-on">preliminary Phase 1 clinical trial data</a>.</li>



<li>Focus Universal (NASDAQ:<a href="https://investorplace.com/stock-quotes/fcuv-stock-quote/">FCUV</a>) shares are plummeting more than 30% on Tuesday morning.</li>



<li>UTime (NASDAQ:<a href="https://investorplace.com/stock-quotes/wto-stock-quote/">WTO</a>) stock is diving over 23% after a major rally yesterday.</li>



<li>Vivos Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/vvos-stock-quote/">VVOS</a>) shares are tumbling more than 22% on a <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318224743&amp;type=PDF&amp;symbol=VVOS&amp;cdn=01c96e38759646a4b342ce7c55cb1bd1&amp;companyName=Vivos+Therapeutics+Inc.&amp;formType=S-1&amp;formDescription=Registration+statement+under+Securities+Act+of+1933&amp;dateFiled=2024-04-09">proposed public offering</a>.</li>



<li>BioSig Technologies (NASDAQ:<a href="https://investorplace.com/stock-quotes/bsgm-stock-quote/">BSGM</a>) stock is taking an over 21% beating on Tuesday.</li>



<li>Maxeon Solar Technologies (NASDAQ:<a href="https://investorplace.com/stock-quotes/maxn-stock-quote/">MAXN</a>) shares are decreasing more than 15% on <a href="https://seekingalpha.com/article/4682824-maxeon-solar-technologies-preliminary-q4-earnings-dont-buy-this-dip?source=content_type%3Areact%7Csection_asset%3Arelated-analysis%7Csection%3Aright_rail%7Cfirst_level_url%3Aarticle%7Cline%3A1%7Cpos%3Aundefined">preliminary earnings results</a>.</li>



<li>Eco Wave Power Global (NASDAQ:<a href="https://investorplace.com/stock-quotes/wave-stock-quote/">WAVE</a>) stock is dropping over 14% after a <a href="https://investorplace.com/2024/04/why-is-eco-wave-power-wave-stock-up-115-today/">massive rally yesterday</a>.</li>



<li>Guardion Health Sciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/ghsi-stock-quote/">GHSI</a>) shares are sliding more than 12% on plans for a <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318223987&amp;type=PDF&amp;symbol=GHSI&amp;cdn=81af5524a2ccf8e9d81bd1343671bec4&amp;companyName=Guardion+Health+Sciences+Inc.&amp;formType=DEFM14A&amp;formDescription=Definitive+proxy+statement+relating+to+merger+or+acquisition&amp;dateFiled=2024-04-08">special shareholder meeting</a>.</li>



<li>DigiAsia (NASDAQ:<a href="https://investorplace.com/stock-quotes/faas-stock-quote/">FAAS</a>) stock is declining almost 12% after a rally yesterday.</li>



<li>Erayak Power Solution (NASDAQ:<a href="https://investorplace.com/stock-quotes/raya-stock-quote/">RAYA</a>) shares close out our pre-market stock movers down over 11%.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/04/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-tuesday-april-9th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

RenovoRx (RNXT) just unveiled an update. On April 11, 2024, the Company successfully completed a notable private placement offering, raising $11.1 ...

RenovoRx Secures $11.1M Through Equity and Warrants Offering

RenovoRx regains compliance with Nasdaq

RenovoRx files to sell 6.96M shares of common stock for holders

Renovorx, Inc. (RNXT) has disclosed a new risk, in the Accounting & Financial Operations category. Renovorx, Inc., a clinical-stage biopharmaceutic...

Biopharmaceutical Challenger Renovorx: Navigating Uncertainty and Financial Risks in Drug Development

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
RenovoRx (NASDAQ:<a href="https://investorplace.com/stock-quotes/rnxt-stock-quote/">RNXT</a>) just reported results for the first quarter of 2024.<ul><li>RenovoRx reported earnings per share of -7 cents. This was above the analyst estimate for EPS of -16 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/rnxt-stock-earnings-renovorx-for-q1-of-2024/">RNXT Stock Earnings: RenovoRx Beats EPS for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

RNXT Stock Earnings: RenovoRx Beats EPS for Q1 2024

RenovoRx (RNXT) just unveiled an announcement. At the 2024 annual meeting, the Company successfully elected six directors to a one-year term with o...

RenovoRx Shareholders Unanimously Elect Board Directors

Edward Woo, an analyst from Ascendiant, has initiated a new Buy rating on RenovoRx (RNXT). Edward Woo has given his Buy rating due to a combination...

Buy Rating Endorsed for RenovoRx: Innovative TAMP Platform and Promising RenovoGem Trials

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
RenovoRx (NASDAQ:<a href="https://investorplace.com/stock-quotes/rnxt-stock-quote/">RNXT</a>) just reported results for the second quarter of 2024.<ul><li>RenovoRx reported earnings per share of -10 cents. This met the analyst estimate for EPS of -10 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/rnxt-stock-earnings-renovorx-for-q2-of-2024/">RNXT Stock Earnings: RenovoRx Meets EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

RNXT Stock Earnings: RenovoRx Meets EPS for Q2 2024

Maxim Group analyst Jason McCarthy maintained a Buy rating on RenovoRx (RNXT – Research Report) yesterday and set a price target of $4.00. Jason Mc...

Buy Rating Backed by RenovoRx's Clinical Advancements and Sustained Financial Health

ACOR

ADXN

ANGH

BCLI

BPTS

BSGM

DXYZ

FAAS

FCUV

GHSI

MAXN

MDIA

MYMD

RAYA

RNXT

VINC

VVOS

WAVE

Press Releases

Publication of Results of Pre-Clinical Studies Support Efficacy and Drug Delivery Mechanism Potential of RenovoRx's TAMP™ Therapy Platform to Improve Targeted Cancer Drug Treatment Delivery

RenovoRx CEO Issues Update Letter to Shareholders

Management

RenovoRx Appoints Ryan Witt as Senior Vice President, Head of Corporate Strategy and Partnerships

University of Nebraska Medical Center Launches Patient Enrollment for RenovoRx's Pivotal Phase III TIGeR-PaC Clinical Trial

Health Care

RenovoRx Announces Acceptance for Publication in the International Peer-Reviewed Journal, The Oncologist®

RenovoRx Announces Publication of Positive Early-Stage Clinical Data in International Peer-Reviewed Journal, The Oncologist®

RenovoRx Announces First Patient Enrolled at University of Nebraska Medical Center for the Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial

RenovoRx CEO Shaun Bagai to Present at H.C. Wainwright's 26th Annual Global Investment Conference on September 9, 2024 in New York

RenovoRx Announces Presentation at Symposium on Clinical Interventional Oncology Highlighting TAMP™ for Targeted Treatment of Locally Advanced Pancreatic Cancer

General

RenovoRx Increases Production of FDA-Cleared RenovoCath® Delivery System in Response to Strong Demand from Oncology and Interventional Radiology Physicians

Comments

RenovoRx

RenovoRx (RNXT) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO